Navlimetostat

Navlimetostat
Clinical data
Other names	MRTX-1719
Identifiers
	IUPAC name (2M)-2-{4-[4-(Aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl]-1-methyl-1H-pyrazol-5-yl}-4-chloro-6-(cyclopropyloxy)-3-fluorobenzonitrile;
CAS Number	2630904-44-6;
PubChem CID	156151242;
IUPHAR/BPS	12116;
DrugBank	DB18016;
ChemSpider	115007150;
UNII	AY4A8WD6JS;
KEGG	D13344;
ChEMBL	ChEMBL5075255;
PDB ligand	85K (PDBe, RCSB PDB);
Chemical and physical data
Formula	C23H18ClFN6O2
Molar mass	464.89 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C(=C(C=N1)C2=CC3=C(C=C2)C(=O)NN=C3CN)C4=C(C(=CC(=C4F)Cl)OC5CC5)C#N;
	InChI InChI=InChI=1S/C23H18ClFN6O2/c1-31-22(20-15(8-26)19(33-12-3-4-12)7-17(24)21(20)25)16(10-28-31)11-2-5-13-14(6-11)18(9-27)29-30-23(13)32/h2,5-7,10,12H,3-4,9,27H2,1H3,(H,30,32); Key:BZKIOORWZAXIBA-UHFFFAOYSA-N;

Navlimetostat is an investigational new drug that is being evaluated by Mirati Therapeutics abd Bristol-Myers Squibb for the treatment of adenocarcinoma.^[1] It is a PRMT5 protein inhibitor.^[1]^[2]^[3]

References

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.